GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: lapatinib, docetaxel, trastuzumab
Sponsor: Novartis Pharmaceuticals